Neoplasms

All Conditions

Rare Diseases

Sarcoma

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Soft Tissue Sarcoma

Antineoplastic Agents

All Drugs and Chemicals

Anti-Infective Agents

Everolimus

Sirolimus

Temsirolimus

MTOR Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Immunosuppressive Agents

Immunologic Factors

RAD001

Given intravenously on Day 1 of a 21-day cycle

CP-751,871

Suzanne George, MD

The purpose of this research study is to determine the safety of the combination of RAD001 and CP-751,871, as well as the highest dose of this combination that can be given to people safely. RAD001 is a newly discovered drug that may stop cancer cells from growing abnormally. This drug has been extensively studied in many cancers. In particular, it has shown to be effective in slowing down the growth of kidney cancer. CP-751,871 is another newly discovered drug that may stop tumor growth. It is currently being studied in a wide variety of cancers, and information from those other research studies suggests that these two drugs in combination may help to stop cancer growth.

* In this research study, each "cycle" of study drug dosing lasts 21 days. In the first cycle, participants will come to the clinic on Days 1, 8, and 15. During cycles 2 through 4, participants will come to the clinic on Days 1 and 8. The rest of the clinic visits will occur on Day 1 of every cycle thereafter.
* During each cycle, participants will take RAD001 orally, once a day in the morning. In addition, participants will receive CP-751,871 intravenously once every cycle on the first day of each cycle.
* Since we are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects, not everyone who participates in this research study will receive the same dose of the study drug. The dose will depend on the number of participants enrolled in the study and how well they tolerated their doses.
* Participants may remain on this research study as long as they do not have serious side effects or their diseae does not get worse.

RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms

Phase I Clinical Trial of RAD001 in Combination With CP-751,871 in Patients With Advanced Sarcomas and Other Malignant Neoplasms

Brigham and Women's Hospital

Novartis

Pfizer

Clinical Director Center for Sarcoma and Bone Oncology

9MW3811 Injection

Xiangdong Cheng, Professor

This is a single ascending dose study of 9MW3811, the primary objective of which is to evaluate the safety, tolerability and preliminary efficacy of 9MW3811 in patients with advanced solid tumors.

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors

An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

A DLT is defined as any of the adverse drug reactions listed in the protocol that will be assessed during Cycle 1

To determine the preliminary efficacy of 9MW3811 following single ascending intravenous doses in patients with advanced solid tumors.

To determine the pharmacokinetic (PK) of 9MW3811 following single ascending intravenous doses in patients with advanced solid tumors.

To determine the immunogenicity of 9MW3811.

Mabwell (Shanghai) Bioscience Co., Ltd.

Antibodies

Antibodies, Bispecific

Immunoglobulins

Each subject will receive a single dose of AK132 every 2-week cycle (Q2W).

IV infusion, specified dose on specified days.

AK132

Zhifang Yao, M.D.

Yu Lin, M.D.

Ruihua Xu, M.D.

Guoxin Li, M.D.

Jingqi Chen, M.D.

Tao Zhang, M.D.

Tienan Yi, M.D.

Yongchang Zhang, M.D.

This is A Phase I Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of The anti-CLDN18.2 and CD47 Bispecific Antibody AK132 in Advanced Malignant Solid Tumor

A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor

A Phase I Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of The Anti-CLDN18.2 and CD47 Bispecific Antibody AK132 in Advanced Malignant Solid Tumor

incidence and severity of DLT, adverse events (AE), serious adverse events (SAE)

Maximum tolerated dose (MTD), Recommended dose for phase II trial

The PK parameters include serum concentrations of AK132 at different timepoints after AK132 administration.

The immunogenicity of AK132 will be assessed by summarizing the number and percentage of subjects who develop detectable antidrug antibodies (ADAs).

ORR is the proportion of subjects with CR or PR based on RECIST v1.1

Duration of response is defined as the duration from the first documentation of objective response to the first documented disease progression (based on RECIST Version 1.1) or death due to any cause, whichever occurs first.

DCR is defined as the proportion of subjects with CR, PR, or SD (based on RECIST Version 1.1).

Time to response (TTR) is defined as the time from the start of the treatment to the first objective tumor response observed for patients who achieved CR or PR (based on RECIST Version 1.1).

PFS is defined as the time from the start of treatment until the first documentation of disease progression or death due to any cause, whichever occurs first (based on RECIST Version 1.1).

OS defined as the time from the first dose to death from any cause.

Akeso

Infections

Symptoms and General Pathology

Malaria

Communicable Diseases

Protozoan Infections

Parasitic Diseases

Mosquito-Borne Diseases

Vector Borne Diseases

Immunomodulating Agents

Antimalarials

This is a single arm study that is planed to enroll 60 patients with advanced malignant solid tumor and each patient will be vaccinated with P.vivax-infected red blood cells containing approximately 0.1-1.0 × 10\^7 Plasmodium parasites. And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples. The treatment will last 5-10 weeks from the day of successful infection and will be terminated by antimalarial drugs.

The patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.1-1.0 × 10\^7 Plasmodium parasites.

Plasmodium immunotherapy

Qin Li, Ph.D

Huang Qiumei, M.D

Hou Jianghou, Ph.D

Xu Jinsong, M.D

The purpose of this study is: 1) to evaluate the effectiveness and extended safety of the Plasmodium immunotherapy for the advanced malignant solid tumors. 2) To explore the safe and effective course of the Plasmodium immunotherapy for the advanced malignant solid tumors. 3) To explore the possible indications of Plasmodium immunotherapy for advanced malignant solid tumors.

The treatment will last 5-10 weeks from the day of successful infection and will be terminated by antimalarial drugs.

This study is planed to enroll 60 patients. Each patient will be vaccinated with 2 ml of P. vivax-infected red blood cells, containing approximately 0.1-1.0 × 10\^7 Plasmodium parasites. The treatment will last for 5-10 weeks from the day of successful infection. During the period of Plasmodium immunotherapy, doctor will use artesunate to control the P. vivax erythrocyte infection rate at a low level, so as to prevent the severe adverse event. After 5-10 weeks, parasitemia will be terminated by antimalarial drugs for ending the treatment of Plasmodium immunotherapy (the immunological treatment effect may persist after the termination of Plasmodium infection). After the treatment, patients will be followed up for 2 years.

Plasmodium Immunotherapy for Advanced Malignant Solid Tumors

Clinical Study of Plasmodium Immunotherapy for Advanced Malignant Solid Tumors

Starting from treatment until the disease progression is first found or the time of any cause of death (disease progression refers to tumor growth, or metastasis of primary tumor, or discovery of new lesions).

The patient's sensitive tumor markers will be reviewed periodically from the time they are enrolled into the study.

The proportion of patients who had a best response rating of complete response, partial response, or stable disease.

Detection of absolute number of immune cells（such as CD3+CD4+、CD3+CD8+ and so on）in peripheral blood by flow cytometry.

Patients are regularly filled with QLQ-C30 (cancer patient quality of life scale) to assess the quality of life of the patients.

The time starting from the treatment to death of whatever causes (when subjects have lost for follow-up before death, the last follow-up time will be calculated as the time of death).

The number of cancer cases remaining after 1 year of treatment / the total number of cancer cases treated \* 100%.

The number of cancer cases remaining after 2 years of treatment / the total number of cancer cases treated \* 100%.

TTP is the time between the beginning of treatment and the onset of tumor progression.

Duration of disease control is the time from the first evaluation of the tumor as CR, PR or SD to the first evaluation as PD (progressive disease) or any cause of death.

Patients are regularly evluated with pain assessment scale

CAS Lamvac Biotech Co., Ltd.

Pembrolizumab

Immune Checkpoint Inhibitors

Antineoplastic Agents, Immunological

Escalating dose levels and backfill cohorts

The BNT314 starting dose for the SRI combination therapy will be one DL lower than the RP2D/MTD/maximum administered dose (MAD) determined from the monotherapy dose escalation.

BNT314

BioNTech clinical trials patient information

BioNTech Responsible Person

The purpose of this first-in-human study is to find out if BNT314 is safe when it is used alone and when it is used together with another antibody cancer drug (pembrolizumab) in patients with different types of cancer. Patients will receive either BNT314 alone or BNT314 combined with pembrolizumab.

Phase 1 of the study consists of a dose escalation part, and a safety run-in (SRI) and expansion part:

Dose escalation: In this part of the study, patients will be assigned to multiple dose levels (DLs) of BNT314 given alone. By escalating the dose with a small group of patients, the Maximum Tolerated Dose (MTD) which is the highest dose with acceptable safety and manageable side effects, or the maximum administered dose (MAD) will be investigated. At the end of this part, the Recommended Phase 2 Dose (RP2D) which is the dose to be tested in Phase 2 will be decided.

Safety Run-In: In this part of the study, BNT314 will be combined with pembrolizumab. Before starting the expansion part, the combination will be tested in another small group of participants (12-28) to find out how safe this combination is.

Expansion: In this part of the study, BNT314 will be combined with pembrolizumab. After the SRI is completed, the study will continue with the expansion part where up to 199 participants with different types of cancer will be included.

The Phase 2 part of the study will be introduced via an amendment to the study protocol.

This is a multicenter, multinational safety study in patients with metastatic or advanced malignant solid tumors for whom, at the discretion of the investigator, there is no available standard therapy likely to confer clinical benefit, evaluating the safety, tolerability, preliminary antitumor activity, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of BNT314.

In the dose escalation part of the study, patients will periodically receive one infusion of BNT314. In the combination therapy SRI and expansion part, BNT314 will be combined with pembrolizumab and administered intravenously in periodic cycles to patients with selected cancer indications.

Additional cohorts (backfill cohorts) administering BNT314 as monotherapy will assign patients to specific DLs, based on the emerging safety, PK, and pharmacodynamic data. This would allow for further assessment of dose- and exposure-response relationships for clinical activity, safety, and tolerability to support BNT314 dose optimization.

The treatment period will last until progressive disease (PD), confirmed PD (as per immune response evaluation criteria in solid tumors \[iRECIST\]), unacceptable toxicity, or withdrawal of consent, whichever happens first.

For the combination therapy, the maximum treatment period will be 2 years. The maximum study duration is 3 years after the last participant's first treatment in the study.

Safety and Preliminary Efficacy of BNT314 With or Without an Immune Checkpoint Inhibitor in Cancer Patients With Malignant Solid Tumors

A First-in-Human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate the Safety and Preliminary Efficacy of BNT314 in Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Patients With Advanced Malignant Solid Tumors

Reported with number and proportion of patients with a confirmed complete response (CR) or partial response (PR) as best overall response.

Reported with number and proportion of patients with a CR, PR, or stable disease (SD) (assessed at least 6 weeks after first dose of study treatment) as best overall response.

Reported with number and proportion of patients with a confirmed CR or PR as best overall response.

DOR is defined as the time from first objective response (CR or PR) to first occurrence of objective tumor progression or death from any cause, whichever occurs first.

Reported with number and proportion of patients with a CR, PR, or SD (assessed at least 6 weeks after first dose of study treatment) as best overall response.

Defined as time from first dose of study treatment to first confirmed disease progression or death from any cause, whichever occurs first.

Defined as the time from first dose of study treatment to death from any cause.

Genmab

BioNTech SE

The starting dose is 0.03 mg/kg every 3 weeks (q3w) and up to 6 dose levels are planned.

Study treatment will be administered as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first.

The starting dose is 0,5 mg/kg every week (q1w) and up to 3 dose levels are planned.

Study treatment will be administered as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first.

The study will start with dose-escalation cohorts to determine the recommended dose for expansion (RDE) or the maximum tolerated dose (MTD).

Once the RDE (or MTD) has been determined, a safety expansion cohort will be opened and additional patients will be treated with MP0317 monotherapy at this dose to confirm safety in a larger population.

Study treatment will be administered every 3 weeks (q3w) as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first. Treatment beyond PD will be allowed as per Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST).

MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen)

The study will start with dose-escalation cohorts to determine the recommended dose for expansion (RDE) or the maximum tolerated dose (MTD).

Once the RDE (or MTD) has been determined, a safety expansion cohort will be opened and additional patients will be treated with MP0317 monotherapy at this dose to confirm safety in a larger population.

Study treatment will be administered every week (q1w) as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first. Treatment beyond PD will be allowed as per Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST).

MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen)

This study is investigating a new experimental therapy, MP0317, a DARPin® drug candidate targeting fibroblast activation protein (FAP) and CD40. Preclinical studies suggest that MP0317 may provide benefit for the treatment of tumors known to express high levels of FAP and for which approved therapies have been exhausted. This is the first study of MP0317 in humans and its main purpose is to test its safety and tolerability in patients with advanced solid tumors. This study will also examine the blood levels of MP0317 at several increasing dose levels and a recommended dose for further development will be determined. The recommended dose will be tested in a second part of the study to confirm safety and to further assess the preliminary biologic and anti-tumor activity.

First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors

A Phase 1, First-in-human, Multicenter, Open-label, Dose-escalation Study to Characterize the Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors

According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0

DLTs will be reviewed as a subset of AEs that occur within 4 weeks after first study drug administration

Based on occurrence of DLTs within an adaptive study design following Bayesian Logistic Regression Model (BLRM)

Based on incidence and nature of DLTs, and incidence, nature, and severity of AEs and SAEs

Including parameters like maximum serum concentration (Cmax), time at Cmax (Tmax), minimal serum concentration (Cmin)

Proportion of participants with complete response (CR) and partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST)

Best overall response (BOR) of CR, PR or stable disease (SD) lasting 4 or more weeks following first study drug administration

For participants with CR or PR, DOR will be calculated as the time from CR or PR to progressive disease (PD) or death.

Time from first study drug administration to PD

Time from first study drug administration to PD or death

Time from first study drug administration to death of any cause

Molecular Partners AG

Death

Antirheumatic Agents

Analgesics

Cyclophosphamide

Fludarabine

Fludarabine phosphate

Interleukin-2

Antineoplastic Agents, Alkylating

Alkylating Agents

Analgesics, Non-Narcotic

Peripheral blood lymphocytes will be collected and neoantigen reactive T cells(NRTs) will be generated in the laboratory;Both Fludarabine 30mg/m2/D and Cyclophosphamide 300mg/m2/D will be i.v. for 3 days before cell infusion; NRTs 0.5\~1 x 10\^10, will be i.v.Q3 weeks for total 4 doses;programmed cell death-1（PD1） inhibitor SHR-1210,200mg,will be i.v. Q3 weeks for total 4 doses,2 day2 prior to each NRTs infusion;Interleukin-2 (IL-2) will be continuous intravenous infused since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit per day.All Patients will receive a total of 4 cycles of treatment.

Neoantigen Reactive T Cells in an expected volume of 100 milliliter（mL） will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.

Neoantigen Reactive T Cells(NRTs)

SHR-1210 200mg will be administered as an intravenous infusion over 60 minutes.

SHR-1210

Fludarabine(FLU) 30mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.

Cyclophosphamide(CTX) 300mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.

Interleukin-2(IL-2)will be continuous intravenous infused since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit per day.

Baorui Liu, M.D & Ph.D

Zhengyun Zou, M.D & Ph.D

Baorui Liu, M.D. & Ph.D

Zhengyun Zou, M.D. & Ph.D

The purpose of this study is to see the safety and efficient of neoantigen reactive T cells (NRTs) combined with programmed cell death-1(PD-1) inhibitor（SHR-1210）in the treatment of Chinese patients with advanced refractory solid tumors.

The tumor-specific "none-self" immunogenic neoantigens encoded by either viral genes or somatic mutation genes, possess the potential to induce specific anti-cancer immunity, including cellular and humoral immune responses. Today, numerous clinical trials demonstrate that although these "none-self" antigens initiate the antigen-specific immunoglobulin G antibodies and cluster of differentiation 4（CD4）+/cluster of differentiation 8（CD8）+T-cells response, not all of them show a clinical benefit in the response rate, progression-free survival or overall survival.Immune tolerance induced by PD-1 or programmed cell death-ligand1（ PD-L1）maybe play a vital role for these negative outcomes.Personalized cell therapy plus checkpoint inhibitors maybe own a breakthrough in the treatment of those malignant diseases without standard options.Our center has successfully established a new method for preparing personalized neoantigen reactive T cells(NRTS) for adoptive cell therapy(ACT). Today, we will carry out a single center single arm clinical prospective study of NRTs combined with PD-1 inhibitor(SHR-1210) for the treatment of Chinese patients with advanced refractory solid tumors. Participants are assigned to receive 4 circles of cell therapy,and prior to each cycle's immunocytes treatment,preconditional chemotherapy and SHR-1210 will be carried out, and IL-2 continuous intravenous infusion（CIV） will also be given for 5 consecutive days after each time's cell infusion. The safety and clinical response rate（RR） are evaluated. Biomarkers and immunological markers are also monitored.

Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors

Single Center Single Arm Clinical Prospective Study of Neoantigen Reactive T Cells (NRTs) Combined With Programmed Cell Death-1（PD-1） Inhibitor in the Treatment of Chinese Patients With Advanced Refractory Solid Tumors

the duration is measured from the time of treatment to the time of death

T cells in the peripheral blood stimulated by tumor antigens for 24 hr，and then Interferon-gama secretion is measured

cytokines are measured by flow cytometry(FCM)

using Common Terminology Criteria for Adverse Events (CTCAE v4.0) in patients

Response Rate（RR） will be evaluated according Response Evaluation Criteria in Solid Tumors

the duration of progression free survival is measured from the time of treatment to the first date that recurrent or progressive disease or for any reason of death is objectively documented.

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Chief physician

Vaccines

Molgramostim

Sargramostim

Adjuvants, Immunologic

Personal Cancer Vaccine: iNeo-Vac-P01 (peptides)+ GM-CSF;

Peptides: 0.1 or 0.3 mg per peptide given on days 1, 4, 8, 15, 22, 78, and 162 for a total of 7 doses. Additional booster vaccines might be administered depending on ethics and patients' potential benefit.

GM-CSF: 40 mcg given 30 minutes before iNeo-Vac-P01.

iNeo-Vac-P01

GM-CSF

This research study is evaluating a new type of cancer vaccine called "Personalized Neoantigen Cancer Vaccine" as a possible treatment for advanced malignant tumor. The purpose of the clinical study is evaluating the safety, tolerability and partial efficacy of the personalized neoantigen cancer vaccine in the treatment of Chinese patients with advanced malignant cancer, so as to provide a new personalized therapeutic strategy for advanced pancreatic cancer patients.

It is known that cancer patients have mutations (changes in genetic material) that are specific to an individual patient and tumor. These mutations can cause the tumor cells to produce proteins that appear very different from the body's own cells. It is possible that these proteins used in a vaccine may induce strong immune responses, which may help the participant's body fight any tumor cells that could cause the cancer to come back in the future. The study will examine the safety of the vaccine when given at several different time points and will examine the participant's blood cells for signs that the vaccine induced an immune response.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms	NCT00927966	Sarcoma Solid Tumor	RAD001 CP-751,871	18 Years -	Dana-Farber Cancer Institute
A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors	NCT05911984	Advanced Malign...	9MW3811 Injecti...	18 Years - 75 Years	Mabwell (Shanghai) Bioscience Co., Ltd.
A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor	NCT06166472	Advanced Malign...	AK132	18 Years - 75 Years	Akeso
Plasmodium Immunotherapy for Advanced Malignant Solid Tumors	NCT04165590	Advanced Malign...	Plasmodium immu...	18 Years - 70 Years	CAS Lamvac Biotech Co., Ltd.
Safety and Preliminary Efficacy of BNT314 With or Without an Immune Checkpoint Inhibitor in Cancer Patients With Malignant Solid Tumors	NCT06150183	Advanced Malign...	BNT314 Pembrolizumab	18 Years -	BioNTech SE
First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors	NCT05098405	Advanced Malign...	MP0317, a tri-s... MP0317, a tri-s...	18 Years -	Molecular Partners AG
A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor	NCT06166472	Advanced Malign...	AK132	18 Years - 75 Years	Akeso
Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors	NCT03171220	Advanced Malign...	Neoantigen Reac... SHR-1210 Fludarabine Cyclophosphamid... Interleukin-2	18 Years - 75 Years	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Safety and Preliminary Efficacy of BNT314 With or Without an Immune Checkpoint Inhibitor in Cancer Patients With Malignant Solid Tumors	NCT06150183	Advanced Malign...	BNT314 Pembrolizumab	18 Years -	BioNTech SE
Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor	NCT03662815	Advanced Malign...	iNeo-Vac-P01 GM-CSF	18 Years - 75 Years	Sir Run Run Shaw Hospital
First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors	NCT05098405	Advanced Malign...	MP0317, a tri-s... MP0317, a tri-s...	18 Years -	Molecular Partners AG

Spots Global Cancer Trial Database for advanced malignant solid tumor